The drug threat to weight loss supplements

This content item was originally published on www.nutraingredients.com, a William Reed online publication.

- Last updated on GMT

Related tags: Medicine, Vice president

Robinson Pharma marketing vice president, Kenn Israel, discusses the recent GlaxoSmithKline petition for weight loss claims be treated as disease claims, and the potential impact of this on the dietary supplement market.

Robinson Pharma marketing vice president, Kenn Israel, discusses the recent GlaxoSmithKline petition for weight loss claims be treated as disease claims, and the potential impact of this on the dietary supplement market.

Related topics: Regulation

Follow us

Products

View more

Webinars